Dr. Jason M Melear

About Jason M Melear

Education:

• Earned an MD from the University of Texas Medical Branch at Galveston in 2009.
• Completed residency in Internal Medicine at the University of Texas Health Science Center at San Antonio in 2012.
• Finished a fellowship in Hematology/Oncology at the University of Texas MD Anderson Cancer Center in 2015.

Experience:

• Practices as a hematologist and oncologist at Texas Oncology - Austin Midtown.
• Member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).

Area of expertise

Affiliated Hospitals

Texas Oncology-Austin Midtown

Texas Oncology, Austin

Clinical Trials Jason M Melear is currently running

Cema-cel

for B-Cell Lymphoma

This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.

Recruiting1 award Phase 25 criteria

IBRX-042

for HPV-Related Cancer

The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administered by injection every 3 weeks for a total of 3 injections.

Recruiting1 award Phase 17 criteria

More about Jason M Melear

Other Doctors you might be interested in

Frequently asked questions